tldrdailynews.com logo

Lilly to Acquire Orna Therapeutics to Accelerate In Vivo CAR-T

1 min read
Source: PR Newswire
Lilly to Acquire Orna Therapeutics to Accelerate In Vivo CAR-T
Photo: PR Newswire
TL;DR

Eli Lilly will acquire Orna Therapeutics in a deal worth up to $2.4 billion in cash, expanding Lilly’s genetic-medicine platform with Orna’s circular-RNA–based in vivo CAR-T technology (ORN-252) designed to treat B cell–driven autoimmune diseases, leveraging lipid nanoparticle delivery for potentially more durable therapeutic protein expression and broader in vivo cell-therapy options.

Topics:businessbiotech-healthcare#biotech-healthcare#car-t#circular-rna#lilly#lipid-nanoparticles#orna-therapeutics
Share this article
  1. Lilly to acquire Orna Therapeutics to advance cell therapies  PR Newswire
  2. Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna  Reuters
  3. Lilly Strikes Deal for Biotech Orna Worth Up to $2.4 Billion  bloomberg.com
  4. Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena  Fierce Biotech
  5. Eli Lilly makes $2.4B bet on RNA tech  Axios

Want the full story? Read the original reporting

Read on PR Newswire